<?xml version='1.0' encoding='utf-8'?>
<document id="22510096"><sentence text="HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians." /><sentence text="With the licensing of the first hepatitis C (HCV) protease inhibitors (PI), telaprevir (TVR) and boceprevir (BOC), cure rates for chronic HCV infection will substantially improve"><entity charOffset="76-86" id="DDI-PubMed.22510096.s2.e0" text="telaprevir" /><entity charOffset="97-107" id="DDI-PubMed.22510096.s2.e1" text="boceprevir" /><entity charOffset="109-112" id="DDI-PubMed.22510096.s2.e2" text="BOC" /><pair ddi="false" e1="DDI-PubMed.22510096.s2.e0" e2="DDI-PubMed.22510096.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22510096.s2.e0" e2="DDI-PubMed.22510096.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22510096.s2.e0" e2="DDI-PubMed.22510096.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22510096.s2.e1" e2="DDI-PubMed.22510096.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22510096.s2.e1" e2="DDI-PubMed.22510096.s2.e2" /></sentence><sentence text=" Human immunodeficiency virus- chronic hepatitis C (HIV-HCV) co-infected patients are in urgent need for these new drugs, because they are facing both severe liver disease and lower response rates than HCV monoinfected patients" /><sentence text=" The currently available efficacy data are however, limited to two phase II trials" /><sentence text=" Fortunately, TVR and BOC appear to be able to improve cure rates in co-infected patients"><entity charOffset="22-24" id="DDI-PubMed.22510096.s5.e0" text="BOC" /></sentence><sentence text=" A major challenge for clinicians will be the management of drug-drug interactions of antiretroviral drugs and new PI" /><sentence text=" As HCV PI are also metabolized by the cytochrome P450 3A4 system interactions are probable as well with non-nucleoside reverse transcriptase inhibitors as with HIV PI" /><sentence text=" To our knowledge, TVR can only be safely used with one protease inhibitor, boosted atazanavir, and also with efavirenz (EFV), although this combination requires TVR dose adjustments"><entity charOffset="84-94" id="DDI-PubMed.22510096.s8.e0" text="atazanavir" /><entity charOffset="110-119" id="DDI-PubMed.22510096.s8.e1" text="efavirenz" /><entity charOffset="121-124" id="DDI-PubMed.22510096.s8.e2" text="EFV" /><pair ddi="false" e1="DDI-PubMed.22510096.s8.e0" e2="DDI-PubMed.22510096.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22510096.s8.e0" e2="DDI-PubMed.22510096.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22510096.s8.e0" e2="DDI-PubMed.22510096.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22510096.s8.e1" e2="DDI-PubMed.22510096.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22510096.s8.e1" e2="DDI-PubMed.22510096.s8.e2" /></sentence><sentence text=" Boceprevir should not be combined with HIV PI and should not be combined with EFV"><entity charOffset="79-81" id="DDI-PubMed.22510096.s9.e0" text="EFV" /></sentence><sentence text=" The approval of TVR and BOC will create new chances of cure also for HIV-HCV co-infected patients"><entity charOffset="25-27" id="DDI-PubMed.22510096.s10.e0" text="BOC" /></sentence><sentence text=" However, the decision who to treat or not has to be taken carefully on the basis of fibrosis stage and previous treatment outcomes" /><sentence text=" In addition, HIV therapy needs to be optimized according to the available drug-drug interaction data" /><sentence text="" /></document>